DexteraAI uses AI-enabled surgical video analysis to objectively characterize the critical subretinal delivery maneuver in retinal gene and cell therapy trials.
We identify procedural patterns that may help explain complications, delivery variability, imaging findings, and favorable or unfavorable clinical outcomes.
Initial focus: subretinal gene and cell therapy trials, including neovascular AMD, geographic atrophy, and inherited retinal disease.
DexteraAI converts routine surgical video into objective procedural biomarkers that help sponsors evaluate whether technical delivery contributed to procedural events, imaging findings, safety signals, and clinical outcomes.
Clinical outcomes reflect therapy, patient biology, dose, and delivery. The delivery variable is often reviewed subjectively and rarely quantified.
Learn more →Existing surgical video is converted into objective measures of instrument behavior during the critical delivery maneuver, including Precision, Smoothness, Instability, and Tremor.
Learn more →Focused on retinal gene and cell therapy programs requiring subretinal delivery, with retrospective analysis of existing trial video as the initial use case.
Learn more →DexteraAI's initial focus is retinal gene and cell therapy programs requiring subretinal delivery. These trials involve high-value biologic products, technically demanding surgery, and narrow regulatory and adoption pathways because established intravitreal therapies already exist for major retinal diseases.
Our current offering is retrospective analysis of the critical subretinal delivery maneuver using existing trial video. No additional intraoperative hardware is required.
Current use centers on retrospective analysis; validated findings can inform later-stage development.
Assess whether a complication or unexpected result occurred with a distinctive procedural phenotype compared with similar uncomplicated cases.
Determine whether favorable cases share reproducible delivery characteristics.
Test whether candidate procedural biomarkers are associated with sponsor-defined safety, imaging, or clinical endpoints.
Use validated findings to inform training, device selection, workflow refinement, and prospective trial design.
Whether you are evaluating a completed trial or planning the next phase, DexteraAI can quantify the critical delivery maneuver and compare it with sponsor-defined procedural, imaging, safety, and clinical endpoints.